JP2023501386A - 肝障害の治療 - Google Patents

肝障害の治療 Download PDF

Info

Publication number
JP2023501386A
JP2023501386A JP2022526136A JP2022526136A JP2023501386A JP 2023501386 A JP2023501386 A JP 2023501386A JP 2022526136 A JP2022526136 A JP 2022526136A JP 2022526136 A JP2022526136 A JP 2022526136A JP 2023501386 A JP2023501386 A JP 2023501386A
Authority
JP
Japan
Prior art keywords
compound
patient
liver
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526136A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501386A5 (enExample
Inventor
フェノー，マルテイン
ワン，ユジン
ジョン，ウェイドン
クルーチャー，ケビン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terns Pharmaceuticals Inc
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of JP2023501386A publication Critical patent/JP2023501386A/ja
Publication of JP2023501386A5 publication Critical patent/JP2023501386A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022526136A 2019-11-08 2020-11-06 肝障害の治療 Pending JP2023501386A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962933277P 2019-11-08 2019-11-08
US62/933,277 2019-11-08
US202063004403P 2020-04-02 2020-04-02
US63/004,403 2020-04-02
PCT/US2020/059522 WO2021092474A1 (en) 2019-11-08 2020-11-06 Treating liver disorders

Publications (2)

Publication Number Publication Date
JP2023501386A true JP2023501386A (ja) 2023-01-18
JP2023501386A5 JP2023501386A5 (enExample) 2023-11-13

Family

ID=75849579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526136A Pending JP2023501386A (ja) 2019-11-08 2020-11-06 肝障害の治療

Country Status (11)

Country Link
EP (1) EP4054567A4 (enExample)
JP (1) JP2023501386A (enExample)
KR (1) KR20220098168A (enExample)
CN (1) CN114667142A (enExample)
AU (1) AU2020380968A1 (enExample)
BR (1) BR112022008639A2 (enExample)
CA (1) CA3160445A1 (enExample)
CL (1) CL2022001167A1 (enExample)
IL (1) IL292459A (enExample)
MX (1) MX2022005407A (enExample)
WO (1) WO2021092474A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4259279A1 (en) 2020-12-14 2023-10-18 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors
TW202539702A (zh) * 2024-03-08 2025-10-16 大陸商上海拓界生物醫藥科技有限公司 靶向ＩＮＨＢＥ的ＲＮＡｉ劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
MX2018011813A (es) * 2016-03-28 2019-01-24 Intercept Pharmaceuticals Inc Medicina obtenida mediante la combinacion de agonista fxr y arb.
WO2018170173A1 (en) * 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
US20210121493A1 (en) * 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
EP3844156A4 (en) * 2018-08-30 2022-06-08 Terns Pharmaceuticals, Inc. TREATMENT OF LIVER DISEASES

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, vol. 256, JPN6024042406, 14 July 2019 (2019-07-14), pages 167 - 205, ISSN: 0005577245 *
J CLIN INVEST., vol. 123, no. 4, JPN6024042409, 2013, pages 1513 - 1530, ISSN: 0005577248 *
J. MED. CHEM., vol. 60, JPN6024042407, 2017, pages 9960 - 9973, ISSN: 0005577246 *
KLUCHER K. ET AL.: "A novel farnesoid X receptor agonist, TERN-101, reduces liver steatosis, inflammation, ballooning an", THE INTERNATIONAL LIVER CONFERENCE POSTER [ONLINE], JPN6024042405, April 2019 (2019-04-01), ISSN: 0005577244 *
TERNS PHARMACEUTICALS TO PRESENT POSITIVE PRECLINICAL DATA ON FXR AGONIST TERN-101 AT THE LIVER MEET, JPN6024042410, 15 October 2019 (2019-10-15), ISSN: 0005577249 *
WORLD J CLIN CASES, vol. 7, no. 13, JPN6024042408, 6 July 2019 (2019-07-06), pages 1571 - 1581, ISSN: 0005577247 *

Also Published As

Publication number Publication date
CN114667142A (zh) 2022-06-24
MX2022005407A (es) 2022-05-24
CL2022001167A1 (es) 2023-02-10
BR112022008639A2 (pt) 2022-07-19
WO2021092474A1 (en) 2021-05-14
IL292459A (en) 2022-06-01
CA3160445A1 (en) 2021-05-14
EP4054567A4 (en) 2024-01-10
KR20220098168A (ko) 2022-07-11
EP4054567A1 (en) 2022-09-14
AU2020380968A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
US20240316025A1 (en) Combination treatment of liver disorders
AU2021273154A1 (en) Combination treatment of liver disorders
JP2024544528A (ja) 肝障害の治療に使用するためのｓｓａｏ阻害剤及びｔｈｒ－ベータアゴニストの組合せ
EP3743064B1 (en) Treatment of proteinuria
EP4429637A1 (en) Treating liver disorders with an ssao inhibitor
KR20220098168A (ko) 간 장애의 치료
Sorbera et al. Dapoxetine hydrochloride
TW200412976A (en) Androgen pharmaceutical composition and method for treating depression
US20220387414A1 (en) Treating liver disorders
EP4166137A1 (en) Therapeutic agent for fatty liver disease
Sato et al. Uptake and metabolism of ciclesonide and retention of desisobutyryl-ciclesonide for up to 24 hours in rabbit nasal mucosa
KR20220054593A (ko) 병용 치료를 위한 화합물
HK40069155A (en) Treatment of proteinuria
HK40031619A (en) Treatment of proteinuria
HK40031619B (en) Treatment of proteinuria
Haddley Lu-AA-21004

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231102

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240315

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241022

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250422